Indivior (INDV) Competitors $11.55 +0.04 (+0.35%) Closing price 04:00 PM EasternExtended Trading$11.50 -0.06 (-0.48%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INDV vs. VRNA, GRFS, KRYS, ADMA, CYTK, ELAN, PCVX, RYTM, PTCT, and RNAShould you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Indivior vs. Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Avidity Biosciences Indivior (NASDAQ:INDV) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends. Does the media favor INDV or VRNA? In the previous week, Verona Pharma had 17 more articles in the media than Indivior. MarketBeat recorded 40 mentions for Verona Pharma and 23 mentions for Indivior. Verona Pharma's average media sentiment score of 1.07 beat Indivior's score of 0.92 indicating that Verona Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma 17 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor INDV or VRNA? Verona Pharma received 325 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 80.96% of users gave Verona Pharma an outperform vote. CompanyUnderperformOutperformIndiviorOutperform Votes11100.00% Underperform VotesNo VotesVerona PharmaOutperform Votes33680.96% Underperform Votes7919.04% Do analysts prefer INDV or VRNA? Indivior presently has a consensus price target of $15.00, suggesting a potential upside of 29.87%. Verona Pharma has a consensus price target of $81.50, suggesting a potential upside of 12.79%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do institutionals & insiders hold more shares of INDV or VRNA? 60.3% of Indivior shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, INDV or VRNA? Indivior has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Is INDV or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Verona Pharma's return on equity of -79.54% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Indivior-3.96% -241.73% 15.09% Verona Pharma N/A -79.54%-43.49% Which has better earnings and valuation, INDV or VRNA? Indivior has higher revenue and earnings than Verona Pharma. Indivior is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndivior$1.17B1.36$2M-$0.31-37.26Verona Pharma$42.28M138.13-$54.37M-$2.16-33.45 SummaryIndivior and Verona Pharma tied by winning 9 of the 18 factors compared between the two stocks. Get Indivior News Delivered to You Automatically Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDV vs. The Competition Export to ExcelMetricIndiviorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-33.007.3222.5118.54Price / Sales1.36241.49397.62103.30Price / Cash4.9465.8538.1834.62Price / BookN/A6.486.734.25Net Income$2M$143.41M$3.22B$248.18M7 Day Performance7.34%2.30%1.58%1.25%1 Month Performance23.13%7.14%4.05%3.76%1 Year Performance-34.49%-2.61%15.75%5.28% Indivior Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDVIndivior3.3449 of 5 stars$11.55+0.3%$15.00+29.9%-34.5%$1.59B$1.17B-33.001,164Earnings ReportShort Interest ↑Analyst RevisionVRNAVerona Pharma2.9073 of 5 stars$60.07+2.0%$75.43+25.6%+366.5%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8946 of 5 stars$7.01-1.0%N/A+8.1%$4.82B$7.21B5.9926,300KRYSKrystal Biotech4.9058 of 5 stars$161.91-4.0%$220.00+35.9%+10.9%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.4633 of 5 stars$19.64-7.8%$22.50+14.6%+265.0%$4.64B$426.45M70.14530Upcoming EarningsOptions VolumeNews CoveragePositive NewsGap UpCYTKCytokinetics4.1759 of 5 stars$37.93-3.9%$81.63+115.2%-30.1%$4.52B$18.47M-7.05250Upcoming EarningsInsider TradeELANElanco Animal Health3.9364 of 5 stars$8.48+0.5%$14.67+73.0%-28.0%$4.21B$4.44B21.209,800Upcoming EarningsShort Interest ↑PCVXVaxcyte3.0357 of 5 stars$30.39-0.8%$136.50+349.2%-40.8%$3.91BN/A-6.61160Upcoming EarningsPositive NewsRYTMRhythm Pharmaceuticals3.703 of 5 stars$60.48-2.0%$74.92+23.9%+64.0%$3.82B$130.13M-13.97140Upcoming EarningsInsider TradePositive NewsPTCTPTC Therapeutics4.0687 of 5 stars$48.19+1.7%$63.77+32.3%+55.0%$3.80B$806.78M-8.111,410Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsRNAAvidity Biosciences2.8518 of 5 stars$28.52+7.0%$66.69+133.8%+35.3%$3.43B$10.90M-9.90190Upcoming EarningsPositive News Related Companies and Tools Related Companies VRNA Alternatives GRFS Alternatives KRYS Alternatives ADMA Alternatives CYTK Alternatives ELAN Alternatives PCVX Alternatives RYTM Alternatives PTCT Alternatives RNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDV) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
